Product Information
MESALAMINE 4 GM/60 ML KIT is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $134.9044 per EA under NDC 45802092949. Its NADAC has been published 181 times since May 18, 2022.
FDA first approved this application on Sep 17, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Mesalamine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802092949
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA076751FDA Approved
9/17/2004
TE Code
AB
On Market Since
8/2/2018
Price Statistics
The NADAC for MESALAMINE 4 GM/60 ML KIT has been published 181 times since May 18, 2022, and over the history we have for it it has risen 16.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $134.9044 per EA |
|---|---|
| All-time high | $135.1980 (Aug 12, 2026) |
| All-time low | $115.2086 (May 22, 2024) |
| 52-week high | $135.1980 |
| 52-week low | $116.3398 |
| Median price | $116.7580 |
| Average price | $119.4105 |
| Largest weekly change | +15.4% (May 20, 2026) |
| Weeks tracked | 181 |
| Tracking since | May 18, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE 4 GM/60 ML KIT?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE 4 GM/60 ML KIT, manufactured by Padagis Israel Pharmaceuticals Ltd, is $134.9044 per EA (NDC 45802092949), effective Sep 30, 2026.
How has the price of MESALAMINE 4 GM/60 ML KIT changed over time?
Over the history we have for it, the NADAC for MESALAMINE 4 GM/60 ML KIT has risen 16.2%. It has been tracked across 181 weekly CMS publications since May 18, 2022.
What are the highest and lowest recorded NADAC prices for MESALAMINE 4 GM/60 ML KIT?
Since May 18, 2022, the NADAC for MESALAMINE 4 GM/60 ML KIT has ranged from a low of $115.2086 (May 22, 2024) to a high of $135.1980 (Aug 12, 2026), with a median of $116.7580 per EA.
Are there cheaper alternatives to MESALAMINE 4 GM/60 ML KIT?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as MESALAMINE 4 GM/60 ML KIT in a comparable dosage form, but none are currently priced below it.
Who manufactures MESALAMINE 4 GM/60 ML KIT?
MESALAMINE 4 GM/60 ML KIT (NDC 45802092949) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.